Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Jim Van Meerten

CareDx Stock Is Up 300% Over the Past Year. Here’s How Much Upside Is Left.

  • CareDx (CDNA) has surged 300% over the past year, driven by robust technical momentum and strong buy signals.
  • CDNA is rated a “Strong Buy” by several analysts, with consensus price targets suggesting up to 12% further upside.
  • Revenue is projected to grow 30.38% this year, with earnings expected to rise 109.19%, supporting the bullish outlook.
  • Technical indicators remain bullish, but high volatility and a trailing price-earnings ratio highlight speculative risk.

Today’s Featured Stock

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.